Abatacept shortage — CA supply status & alternatives

Abatacept

ATC L04AA24

🇦🇺 AUST R 130100 · Bristol-Myers Squibb Australia Pty Ltd

In supply · Australia

Orencia

In supply · 🇦🇺 Australia · short in🇨🇦 CA🇩🇪 DE

In supply in Australia

Reading today’s signals…

🇦🇺 AUAEMPA$262.40details →

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Abatacept
Brand names	Orencia
ATC level 5	L04AA24
ATC level 4	L04AA
Therapeutic category	Auto-created by Bundesinstitut für Arzneimittel und Medizinprodukte — Lieferengpässe scraper
Controlled substance	No
Marketing-authorisation holders	Bristol-Myers Squibb Australia Pty Ltd
Registrations on file	2
Patient information leaflet (PIL)	Not on file
Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 PBS · July 2026

🇦🇺 AU

● Official price on file

Ex-manufacturer

A$262.40

AEMP

Dispensed (DPMQ)

—

incl. fees

Pack

abatacept 250 mg injection, 1 vial

Source: PBSEffective July 2026 · AUD

Other markets

🇺🇸 US

US$1470.78

Acquisition

🇫🇷 FR

€947.88

Retail price

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

FDA-approved products 🇺🇸 Drugs@FDA

Approved applications

Generic (ANDA)

Brand (NDA/BLA)

Aug 2011

Latest approval

Shortage status by regulator official notices

🇨🇦

Canada

HC · 5h ago

High

🇩🇪

Germany

BfArM · 3d ago

High

Verified timeline regulator events

🇩🇪 8 June 2026

high reported

🇨🇦 28 Apr 2026

high reported

Sources official regulators

🇨🇦

verified 5h ago

verify ↗

🇩🇪

BfArM

verified 3d ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders2 registrations · 1 MA holder

Product	Strength	Form	Market	MA holder	Status
ORENCIA abatacept	250 mg	—	🇦🇺 AU	Bristol-Myers Squibb Australia Pty Ltd	Active
ORENCIA abatacept	125 mg	—	🇦🇺 AU	Bristol-Myers Squibb Australia Pty Ltd	Active

Mederti Drug Report

Generated 3 July 2026 · Australia market · 2 regulatory sources

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.